Clinical Trial Highlights

• Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF
• Prednisolone but Not PTX Improves 28-Day Mortality in Patients with Alcoholic Hepatitis
• DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results
• Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3
• SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
• Sebelipase Alfa Normalizes ALT and Multiple other Disease-Related Abnormalities in Patients with LAL-D
• Sustained Virologic Response of 91% in Patients Infected with HCV Treated with DCV-TRIO
• Uniform Downstaging Protocol Produces Excellent Posttransplantation Outcomes in HCC
• SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6
• Terlipressin and Albumin Combination Therapy Improves Renal Function in HRS-1
• Direct-Acting Antiviral Therapy Produces High SVR12 in HCV GT-1 Cirrhotic Patients Regardless of Baseline Characteristics
• Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
• SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients
• HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF
• 100% SVR with Ledipasvir/Sofosbuvir Plus Ribavirin in Patients with HCV GT-1 Failing Prior Therapy
• High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection
• Interferon- and RBV-Free Treatment with LDV and SOF is Efficacious in Patients Coinfected with HCV and HIV